ライフサイエンスコーパス: lymphocytosis

1 rognostic factor associated with progressive lymphocytosis.

2 eristic lymphocyte clone and the presence of lymphocytosis.

3 mal blood count and 13.9% (309 of 2228) with lymphocytosis.

4 50% of cases of CD4(+) T-cell large granular lymphocytosis.

5 microl), with 56% of patients experiencing a lymphocytosis.

6 ammation, often granulomatous, and meningeal lymphocytosis.

7 vels with only a few cases developing marked lymphocytosis.

8 okine production by T cells and induction of lymphocytosis.

9 an indolent lymphoma with monoclonal B-cell lymphocytosis.

10 (-/-) mice failed to develop splenomegaly or lymphocytosis.

11 velopment and/or maintenance of persistent B lymphocytosis.

12 e with the preneoplastic syndrome persistent lymphocytosis.

13 phadenopathy or significant peripheral blood lymphocytosis.

14 a significant decrease of monoclonal B-cell lymphocytosis.

15 1 IWCLL partial response (PR) and 3 PRs with lymphocytosis.

16 onse criteria modified for treatment-related lymphocytosis.

17 ymerase chain reaction and leukocytosis with lymphocytosis.

18 68%; 38 (34%) of 111 patients had transient lymphocytosis.

19 who achieved nodal response with persistent lymphocytosis.

20 on samples from nine patients with prolonged lymphocytosis.

21 sulted in the near abolishment of the B cell lymphocytosis.

22 treated patients had a partial response with lymphocytosis.

23 espective groups had a partial response with lymphocytosis.

24 ed by a more benign monoclonal CD5(+) B-cell lymphocytosis.

25 taken into account when considering duodenal lymphocytosis.

26 que family with hereditary polyclonal B cell lymphocytosis.

27 e the CLL precursor lesion monoclonal B cell lymphocytosis.

28 than 50% in 19 of 21 patients with baseline lymphocytosis.

29 romote cell proliferation and does not cause lymphocytosis.

30 g rapid lymph node shrinkage and a transient lymphocytosis.

31 n the preleukemic state of monoclonal B-cell lymphocytosis.

32 RC3 lesions were absent in monoclonal B-cell lymphocytosis (0 of 63) and were rare in CLL at diagnosi

33 pdated criteria of PR with treatment-induced lymphocytosis.(1,2) The median progression-free survival

34 hemotherapy, 13 patients with large granular lymphocytosis, 20 controls who had received renal allogr

35 Vitrectomy showed reactive lymphocytosis (4/4), predominantly CD4(+) (1/1).

36 leucocytosis (64 versus 22%, P: < 0.05), CSF lymphocytosis (64 versus 42%, not significant) and CSF p

37 is (frequency 99.9%, 95% CI 68.5-100.0), CSF lymphocytosis (97.9%, 51.9-100.0), fever (89.8%, 79.8-95

38 CLL cases and 54 patients with monoclonal B-lymphocytosis, a precursor disorder.

39 f IL-2 administered, and the maximal rebound lymphocytosis after cessation of IL-2 correlated with ac

40 ons after DLI developed a significant B-cell lymphocytosis after treatment, which did not occur in pa

41 The precursor condition, monoclonal B-cell lymphocytosis, also aggregates in CLL families.

42 had raised CSF protein levels and 73% had a lymphocytosis, although 57% of all submitted samples sho

43 Bronchoalveolar lavage fluid showed lymphocytosis and a low CD4/CD8 ratio.

44 There is leukocytosis with lymphocytosis and apneic episodes.

45 These changes correlated with pulmonary lymphocytosis and clinical measures of disease severity,

46 D and correlate with the degree of pulmonary lymphocytosis and clinical measures of disease severity.

47 BAL lymphocytosis and computed tomography (CT) scan findings

48 characterized by chronic cerebrospinal fluid lymphocytosis and elevated levels of the antiviral cytok

49 We suggest that both massive lymphocytosis and excessive lymphocyte activation could

50 Both massive lymphocytosis and excessive lymphocyte activation could

51 , the authors discuss the current work-up of lymphocytosis and highlight how to use recently identifi

52 h upon repeated TCR engagement and pulmonary lymphocytosis and hyperinflammation in Mtb-infected mice

53 ) patients with CD4(+) T-cell large granular lymphocytosis and implicate cytomegalovirus as a likely

54 le of cytomegalovirus (CMV) infection in CD8 lymphocytosis and inflammation in ART-treated HIV infect

55 y of patients, even before the occurrence of lymphocytosis and irrespective of the clonotypic IGH var

56 OR1 x TCL1) developed CD5(+)B220(low) B-cell lymphocytosis and leukemia at a significantly younger me

57 We observed that heparin induced both lymphocytosis and neutrophilia, and the effects required

58 Leukocytosis with lymphocytosis and pneumonia are commonly observed among

59 HC-MBL is associated with lymphocytosis and progresses to CLL requiring treatment

60 account for a significant proportion of the lymphocytosis and provide molecular evidence that these

61 rently healthy Ppp1r18-/- mice that manifest lymphocytosis and reduced population of peripheral lymph

62 cells' survival during BTK inhibitor-induced lymphocytosis and/or playing a role in therapy resistanc

63 itive group, 17 animals exhibited persistent lymphocytosis, and 100% of these were herpesvirus positi

64 mice deficient in IL-2 exhibit splenomegaly, lymphocytosis, and autoimmunity, suggesting this cytokin

65 ans, including CLL, CD5(+) monoclonal B-cell lymphocytosis, and CD5(-) non-Hodgkin lymphomas.

66 d serial samples during ibrutinib-associated lymphocytosis, and identified clades of cells that were

67 of antigen exposure, bronchoalveolar lavage lymphocytosis, and lung biopsy demonstrating granulomas,

68 nd that medullary carcinoma, intraepithelial lymphocytosis, and poor differentiation were the best di

69 is model, PCI-32765 caused a transient early lymphocytosis, and profoundly inhibited CLL progression,

70 staining included marked tumor infiltrating lymphocytosis, and solid/cribiform or signet ring histol

71 receiving ibrutinib who have residual clonal lymphocytosis, and that clinical trials are needed to ev

72 hypergammaglobulinemia, autoimmunity, B-cell lymphocytosis, and the expansion of an unusual populatio

73 ures are associated with cerebrospinal fluid lymphocytosis, and the later features with appearance of

74 expand, suggesting that the profound CD8(+) lymphocytosis associated with acute EBV infection is com

75 in subjects with CLL-phenotype MBL and with lymphocytosis at the rate of 1.1% per year.

76 evelop an early-onset indolent CD5(+) B-cell lymphocytosis attributed to a defect in secondary V(D)J

77 e shrinkage, along with a transient surge in lymphocytosis, before inducing objective remissions.

78 Most interestingly, 5 patients had a delayed lymphocytosis between day 30 and day 120 after HCT.

79 or complement factors C1q, monoclonal B-cell lymphocytosis, C2, C4, C4b, C3, C3a, Factor B, Bb, Facto

80 ting latently infected B cells, and a marked lymphocytosis caused by hyperexpansion of EBV-specific C

81 rcinoma, three (9%) cases of benign reactive lymphocytosis confirmed at open biopsy, and one (3%) cas

82 reduced CD4+ CD45RA+ T cells, and CD8+ CD57+ lymphocytosis, confirming the concept of a subgroup of p

83 In the mouse model, this lymphocytosis consists of highly activated CD8+ T cells

84 symptomatic, and blood viral load and CD8(+) lymphocytosis correlated with disease severity.

85 The massive lymphocytosis could be the result of nonadapted or uncon

86 s with these conditions have intraepithelial lymphocytosis, crypt hyperplasia, and severe intestinal

87 CL3, CCL4, and CXCL13 levels, and a surge in lymphocytosis during CAL-101 treatment.

88 characterization of patients with persistent lymphocytosis during ibrutinib therapy.

89 SOX11(-) MCL had a higher frequency of lymphocytosis, elevated level of lactate dehydrogenase (

90 ubcutaneous infusion produced a much greater lymphocytosis, elevation in acute-phase reactants, and f

91 umor-bearing animals resulted in a transient lymphocytosis, followed by a clear reduction in tumor in

92 e understanding of how SAP deficiency causes lymphocytosis following EBV infection.

93 cells isolated from patients with prolonged lymphocytosis following ibrutinib therapy.

94 llus architecture, increased intraepithelial lymphocytosis, goblet cell depletion, Paneth cell deplet

95 a normal blood count and 2228 subjects with lymphocytosis (>4000 lymphocytes per cubic millimeter) f

96 In the mouse model, this lymphocytosis has two distinct components: an early, con

97 the general population and in subjects with lymphocytosis have features in common with CLL cells.

98 Evaluation of intraepithelial duodenal lymphocytosis (IDL) is important in celiac disease (CD).

99 only to subcutaneous and/or cutaneous sites, lymphocytosis immediately after treatment, and long-term

100 18 patients (55%) and partial response with lymphocytosis in 14 (42%).

101 in vitro, and (4) is associated with delayed lymphocytosis in a subset of patients.

102 rheumatoid factor at onset of lung disease, lymphocytosis in bronchoalveolar lavage fluid (BALF), an

103 ported by positive precipitating antibodies, lymphocytosis in bronchoalveolar lavage fluid, and chara

104 On the basis of clinical course, lymphocytosis in bronchoalveolar lavage fluid, and drug-

105 ) inhibitor therapy induces peripheral blood lymphocytosis in chronic lymphocytic leukemia (CLL), whi

106 12 that causes a transient, mononuclear cell lymphocytosis in experimentally infected cattle.

107 n Bangladesh and more marked intraepithelial lymphocytosis in Pakistan.

108 pecific CD4+ T(EM) cells in blood and T cell lymphocytosis in the lung.

109 A CD8+ T cell lymphocytosis in the peripheral blood is associated with

110 granulomatous lung lesions, peribronchiolar lymphocytosis, increased cell concentrations in lavage,

111 mmune activation was induced, as measured by lymphocytosis, increased peripheral-blood natural killer

112 cella antibodies in CSF; (3) the presence of lymphocytosis, increased protein, and decreased glucose

113 alatine petechiae, splenomegaly, or atypical lymphocytosis is associated with an increased likelihood

114 vine leukemia virus (BLV)-induced persistent lymphocytosis is characterized by a polyclonal expansion

115 Thus, prolonged lymphocytosis is common following ibrutinib treatment, l

116 ion characteristic of BLV-induced persistent lymphocytosis is IL-2 dependent and antigen dependent.

117 Conclusions: BAL lymphocytosis is rare in patients with extensive fibrosi

118 the majority of patients, but a subgroup has lymphocytosis lasting >12 months.

119 ymphoma cells associated with redistribution lymphocytosis, leading to more potent antitumour activit

120 ction, including oral transmission, atypical lymphocytosis, lymphadenopathy, activation of CD23(+) pe

121 PHIP had extensive lymphocytosis marked by massive expansion of natural kil

122 logic entity usually characterized by marked lymphocytosis, massive splenomegaly, an aggressive cours

123 ria to distinguish between monoclonal B-cell lymphocytosis (MBL) and CLL could minimize patient distr

124 c lymphocytic leukemia (CLL) or monoclonal B-lymphocytosis (MBL) have impaired response to COVID-19 v

125 Monoclonal B-cell lymphocytosis (MBL) is a common hematological premaligna

126 Monoclonal B-cell lymphocytosis (MBL) is a precursor lesion that can be sc

127 Monoclonal B-cell lymphocytosis (MBL) is a precursor of chronic lymphocyti

128 c leukemia (CLL)-phenotype monoclonal B-cell lymphocytosis (MBL) is a premalignant condition that is

129 Monoclonal B lymphocytosis (MBL) is defined as the presence of a clon

130 s with Rai 0 stage CLL and monoclonal B-cell lymphocytosis (MBL) is unclear.

131 The diagnosis of monoclonal B-cell lymphocytosis (MBL) is used to characterize patients wit

132 k haplotype exhibited CD5+ monoclonal B-cell lymphocytosis (MBL) on flow cytometry.

133 Monoclonal B-cell lymphocytosis (MBL) progresses to chronic lymphocytic le

134 cytic leukemia (CLL) -like monoclonal B-cell lymphocytosis (MBL) shares common immunophenotype and cy

135 ved in the transition from monoclonal B-cell lymphocytosis (MBL) to CLL and tested miR-15a/16-1 clust

136 kemia (CLL) is preceded by monoclonal B-cell lymphocytosis (MBL), a CLL precursor state with a preval

137 Monoclonal B-cell lymphocytosis (MBL), a newly recognized entity found in

138 Monoclonal B-cell lymphocytosis (MBL), the precursor to CLL, has a higher

139 been designated as having monoclonal B-cell lymphocytosis (MBL).

140 r CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL).

141 adults, a condition called monoclonal B-cell lymphocytosis (MBL).

142 ated genes in CLL (5.3%) and in monoclonal B lymphocytosis (MBL, 7%), a B-cell expansion that can evo

143 Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined sig

144 t(14;18) translocation and monoclonal B-cell lymphocytosis, no clear link between the presence of abe

145 s presenting with lymphocytosis, progressive lymphocytosis occurred in 51 (28%), progressive CLL deve

146 p more advanced disease such as a persistent lymphocytosis of B cells or B-cell lymphosarcoma.

147 leukosis in animals that develop persistent lymphocytosis of B cells or B-cell lymphosarcoma.

148 ound to be elevated (to 20 K) with sustained lymphocytosis of mature phenotype.

149 Neither eosinophilia nor lymphocytosis on BAL was associated with mortality, rapi

150 D8+ T-lymphocyte ratio, and marked pulmonary lymphocytosis on histologic examination when compared wi

151 atory CLL cell survival and a more prominent lymphocytosis on therapy.

152 -associated viral loads without a marked CD8 lymphocytosis or NK cell disturbance like those seen in

153 ontrary, eosinophilia (OR, 1.6; P = 0.0002), lymphocytosis (OR, 1.84; P = 0.0002), increased erythroc

154 th both blood EBV load (P = .015) and CD8(+) lymphocytosis (P = .0003).

155 Additionally, during persistent lymphocytosis, peak IL-2 and IL-10 mRNA expression was d

156 disease categories such as monoclonal B-cell lymphocytosis (peripheral blood clonal lymphocytosis tha

157 ssociated with the development of persistent lymphocytosis (PL) and lymphoma in cattle.

158 CD5(+) B-cell population, termed persistent lymphocytosis (PL).

159 e mechanism of leukemogenesis and persistent lymphocytosis (PL; benign expansion of B lymphocytes) in

160 rticipants with persistent polyclonal B cell lymphocytosis (PPBL).

161 patients are preceded by a monoclonal B-cell lymphocytosis precursor state, patterns of immune defect

162 We found increased BAL lymphocytosis, predominantly CD4+ T cells, in CIP.

163 antly higher prevalence of monoclonal B cell lymphocytosis, premalignant condition poorly described i

164 Inhibitory cytokines and lymphocytosis present in chronic tuberculosis inflammati

165 Among 185 subjects presenting with lymphocytosis, progressive lymphocytosis occurred in 51

166 ve form of BENTA features exaggerated B-cell lymphocytosis relative to monoallelic BENTA.

167 Treatment-related lymphocytosis remains largely asymptomatic even when per

168 Most patients experience lymphocytosis, representing lymphocyte egress from nodal

169 of therapy, and subsequently, his peripheral lymphocytosis resolved and CLL regressed.

170 The presence of atypical lymphocytosis significantly increases the likelihood of

171 hepatitis C infection, including sinusoidal lymphocytosis, steatosis, portal lymphoid aggregates/fol

172 btained from patients with monoclonal B-cell lymphocytosis, suggesting a role for LEF-1 early in CLL

173 sponse to HIV-1, termed diffuse infiltrative lymphocytosis syndrome (DILS), which resembles autoimmun

174 f spondyloarthritis and Diffuse Infiltrative Lymphocytosis Syndrome has decreased, whereas the muscul

175 V-infected persons with diffuse infiltrative lymphocytosis syndrome, a disease in which host immunoge

176 er manifestation of the diffuse infiltrative lymphocytosis syndrome, usually associated with a milder

177 atients had concomitant diffuse infiltrative lymphocytosis syndrome.

178 Monoclonal B-cell lymphocytosis, t(14;18) translocation, and abnormal free

179 ay marked lymphadenopathy, splenomegaly, and lymphocytosis, TDAG51-/- mice had no apparent defects in

180 A transient lymphocytosis that correlated with peak virus detection

181 -cell lymphocytosis (peripheral blood clonal lymphocytosis that does not meet other criteria for CLL)

182 e, many studies have attempted to define the lymphocytosis that occurs during acute EBV infection in

183 cluding 1 patient with partial response with lymphocytosis, the best ORR was 96.7%.

184 This illness is characterized by a striking lymphocytosis, the nature of which has been controversia

185 esponse and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable d

186 sponse and six (40%) a partial response with lymphocytosis; the remaining three (20%) patients had st

187 /P212fs) mice exhibit systemic inflammation, lymphocytosis, vasculitis, and kidney disease.

188 is not inferior for patients with prolonged lymphocytosis vs those with traditional responses.

189 Cell mobilization studies revealed that the lymphocytosis was attributable to a combination of block

190 CI, 76.8 to 86.7) when partial response with lymphocytosis was included.

191 Lymphocytosis was reduced by more than 50% in 19 of 21 p

192 Although the absolute lymphocytosis was resolved in all patients by week 4, si

193 s with late-stage disease, termed persistent lymphocytosis, was significantly decreased compared to t

194 D4/CD8 ratio, increased blood CD8 count, and lymphocytosis were additional biomarkers highly correlat

195 t of 185 subjects with CLL-phenotype MBL and lymphocytosis were monitored for a median of 6.7 years (

196 morrhagic lesions, and cerebral spinal fluid lymphocytosis were significantly associated with HSV/VZV

197 etermined significance and monoclonal B-cell lymphocytosis, which are precursor states for hematologi

198 egories: chronic T-cell leukemia and NK-cell lymphocytosis, which are similarly indolent diseases cha

199 of lymphadenopathy accompanied by transient lymphocytosis, which is reversible upon temporary drug d

200 found in any of the patients with prolonged lymphocytosis who were taking ibrutinib.

201 and clinical significance of a clonal B-cell lymphocytosis with an immunophenotype consistent with ma

202 Polyclonal B cell lymphocytosis with expansion of CD5+ B cells was a chara

203 ow cytometry showed that BIV causes a B-cell lymphocytosis with no consistent, significant changes in

204 sponse rate, including partial response with lymphocytosis, with acalabrutinib was 94%; responses wer

205 IL-2 induced lymphocytosis, with an increase in CD56+ and CD8+ cells.

206 (KO) mice develop a progressive nonlethal B lymphocytosis, with expansion of B220(+) cells in the bo